Next Article in Journal
Flow Cytometry: From Experimental Design to Its Application in the Diagnosis and Monitoring of Respiratory Diseases
Next Article in Special Issue
Prominent Role of Histone Modifications in the Regulation of Tumor Metastasis
Previous Article in Journal
Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 21
Issue 22
10.3390/ijms21228829
Review Report
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Clinical Perspectives of ERCC1 in Bladder Cancer

Int. J. Mol. Sci. 2020, 21(22), 8829; https://doi.org/10.3390/ijms21228829
by Konstantinos Koutsoukos 1, Angeliki Andrikopoulou 1, Nikos Dedes 1, Flora Zagouri 1, Aristotelis Bamias 2 and Meletios-Athanasios Dimopoulos 1,*
Reviewer 1:
Maciej Salagierski
Reviewer 2:
Petros Grivas
Int. J. Mol. Sci. 2020, 21(22), 8829; https://doi.org/10.3390/ijms21228829
Submission received: 17 September 2020 / Revised: 12 November 2020 / Accepted: 18 November 2020 / Published: 22 November 2020
(This article belongs to the Special Issue Causalities and Regulations of Tumor Metastasis — in Memory of Professor Isaiah J. Fidler (1936–2020))

Round 1

Reviewer 1 Report

could you please describe the methodology of selecting the articles for your review- which criteria were taken into account, how many articles were selected?

key words - breast cancer- is it necessary?

I would advise to shorten the manuscript considerably and concentrate mainly on clinical aspects of ERCC1,  you could also discuss this application of other potential markers of BCa

the title could be also more informative if possible i.e. clinical implications of ERCC1 in bladder cancer?

 

 

Author Response

"Please see the attachment."

Author Response File: Author Response.pdf

Reviewer 2 Report

Comprehensive nice review of the role of ERCC1 as a putative biomarker in bladder cancer. The review is relevant to broader biomarker discussions in the field and seems very detailed, including relevant literature. It is organized well, so it is easy to follow. Minor revisions suggested:

  1. Would mention a bit more about ERCC2, ATM, Rb1, FANCC, or other DDR gene mutations as potential predictors of response to cisplatin based chemotherapy, which are currently being in tested in 3 neoadjuvant trials
  2. Consider commenting on ERCC1 & other DDR genes and PARP inhibitors and briefly discuss/cite BISCAY trial https://oncologypro.esmo.org/meeting-resources/esmo-2019-congress/An-adaptive-biomarker-directed-platform-study-in-metastatic-urothelial-cancer-BISCAY-with-durvalumab-in-combination-with-targeted-therapies and ATLAS trial https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.6_suppl.440 & 
  3. Line 379-380: ERCC1 has been studied extensively as the authors show but has not been useful yet in practice, so would rephrase that sentence
  4. Any comments about ERCC1 and response to checkpoint inhibitors?
  5. Avoid phrasing "cancer patients" but rather use "patients with cancer" as per patient advocacy groups
  6. Any comments about ctDNA as a tool complementary to tissue aiming to capture tumor heterogeneity and monitor alterations in ERCC1 gene?

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Round 2

Reviewer 1 Report

thanks for the revised version of the manuscript

Back to TopTop